George Bailes, MD
Family Medicine · Spartanburg, SCNPI 1417935339
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,000 of the $22,480 with a category attached, or 66.7%. G1 Therapeutics, Inc. accounts for 66.7% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $16,108 and has fallen 94.2% since, to $942 in 2025. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 472 payments — averaging $47.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- G1 Therapeutics, Inc.$15K
- AbbVie$847
- Pfizer$617
- Novo Nordisk$584
- AstraZeneca$489
- GSK$486
- plus $4K from 54 others
What the payments were for
- Consulting fees$15,00067%
- Food & beverage$7,47933%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSELA$15,000
How this compares
$22,480 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $96,249 |
| EliquisApixaban | 77 | $79,659 |
| FarxigaDapagliflozin Propanediol | 38 | $33,198 |
| MounjaroTirzepatide | 14 | $26,548 |
| XareltoRivaroxaban | 26 | $20,766 |
| TradjentaLinagliptin | 18 | $20,362 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $19,493 |
| TrulicityDulaglutide | 21 | $19,275 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $14,435 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $13,983 |
| MyrbetriqMirabegron | 16 | $12,947 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $9,973 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,176 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $9,034 |
| Repatha SureclickEvolocumab | 16 | $8,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $584 | $96,24961 claims |
| PfizerEliquis | $617 | $79,65977 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $171 | $49,81454 claims |
| Boehringer IngelheimTradjenta, Glyxambi | $206 | $34,34530 claims |
| AstraZenecaFarxiga | $489 | $33,19838 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta | $486 | $25,77347 claims |
| Johnson & JohnsonXarelto | $51 | $20,76626 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $12,94716 claims |
| AbbVieSynthroid | $847 | $3,67752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Spartanburg
- Latasha SelibySpartanburg$24K
- Mark KnipferSpartanburg$15K
- Thomas NowatkaSpartanburg$13K
- Baker BolesSpartanburg$13K
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.